Literature DB >> 10172868

A practical guide for calculating indirect costs of disease.

M A Koopmanschap1, F F Rutten.   

Abstract

There may be some discussion about whether indirect costs should be taken into account at all in an economic appraisal, but there is certainly considerable debate about the proper way of estimating these costs. This reviews offers a practical guide for quantifying and valuing these indirect costs of disease, both at an aggregated level of general cost of illness studies, and in an economic appraisal of specific healthcare programmes. Two methods of calculating these costs are considered: the traditional human capital approach, and the more recently developed friction cost method. The former method estimates the potential value of lost production as a result of disease, whereas the latter method intends to derive more realistic estimates of indirect costs, taking into account the degree of scarcity of labour in the economy. All necessary steps in the estimation procedure and the data required at various points will be described and discussed in detail.

Entities:  

Mesh:

Year:  1996        PMID: 10172868     DOI: 10.2165/00019053-199610050-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  7 in total

1.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

2.  Cost-of-illness studies: a major headache?

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

3.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

4.  Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire.

Authors:  L van Roijen; M L Essink-Bot; M A Koopmanschap; G Bonsel; F F Rutten
Journal:  Int J Technol Assess Health Care       Date:  1996       Impact factor: 2.188

Review 5.  The impact of indirect costs on outcomes of health care programs.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Health Econ       Date:  1994 Nov-Dec       Impact factor: 3.046

6.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

7.  The cost of diabetes.

Authors:  K Gerard; C Donaldson; A K Maynard
Journal:  Diabet Med       Date:  1989-03       Impact factor: 4.359

  7 in total
  120 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 3.  Economic Notes: opportunity cost.

Authors:  S Palmer; J Raftery
Journal:  BMJ       Date:  1999-06-05

Review 4.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

Review 5.  The economic cost of epilepsy: a review.

Authors:  M Brunetti; E Pagano; L Garattini
Journal:  Ital J Neurol Sci       Date:  1998-04

6.  Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: cost effectiveness.

Authors:  P Bower; S Byford; B Sibbald; E Ward; M King; M Lloyd; M Gabbay
Journal:  BMJ       Date:  2000-12-02

7.  [Economic aspects of ambulatory and inpatient treatment of HIV positive patients].

Authors:  M Stoll; R E Schmidt
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

8.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.

Authors:  M J Postma; J M Bos; R Welte; R de Groot; W Luytjes; H C Rümke; P Beutels
Journal:  Eur J Health Econ       Date:  2004-02

Review 10.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.